drugset / Trial / NCT05440734

Exogenous Melatonin in Postmenopausal Women with Insomnia

NCT05440734

RandomizedCrossoverTriple-blindTreatment

Summary

The aim of the study is to assess the effect of exogenous melatonin, 2 mg SR, 60 minutes before bedtime for 15 days, on the sleep and circadian rhythms of postmenopausal women with insomnia in a randomized crossover placebo-controlled study.

Timeline

Start
2022-06-17
Primary completion
2024-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Melatonin Small molecule 2 mg Oral

Indications